• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Technology

Building a Sweet 16 Portfolio, Part 1

Selection of stocks is tailor made for investor, given market parameters.
By JIM COLLINS
Jul 23, 2015 | 08:00 AM EDT
Stocks quotes in this article: AAPL, ABX, DHT, DFT, FB, MSFT, YHOO, GDP, MHR, MNKD, SNY, NEWT, EYES

I just constructed a new portfolio for an international client. For a number of reasons I can't disclose, I was limited to U.S. equities on a long-only basis. So, no preferreds, no ETFs, no hedging with call options, etc. A few colors were removed from my palette, but Portfolio Guru LLC is all about adapting to individual client circumstances. I construct each portfolio based on the individual needs of the client, and the restrictions from my newest charge were not terribly onerous.

The broad U.S. market indices are clearly overvalued, earnings have been underwhelming -- thanks, Apple (AAPL) -- interest rates don't reflect the true risk of borrowing money, and the recent plunge in commodity prices is disturbing. Other than that, I'm pretty sanguine these days! But, hey, I had a job to do, so I did it.

I certainly don't see much near-term upside for this market, so I leaned heavily on my income-investing principles in the construction of his portfolio. We'll beat a flat market because of the portfolio's yield of about 5%, and we should substantially outperform a declining market due to the portfolio's low risk profile.

So, against that backdrop, I gave my new client a Sweet 16 of U.S. stocks. Owing to space constraints, I'll discuss eight today and eight in tomorrow's column. Here they are:

Barrick Gold (ABX): Oh my God, did I really buy a gold stock? When something hits a 25-year low, you have to at least take a look. ABX's 2.7% yield fits in well and there is upside when/if gold prices recover.

DHT Holdings (DHT): Low crude prices benefit oil shippers more than any other sector, and DHT's fleet of VLCC tankers is perfectly positioned. Current yield is 6.79%, and DHT management announced Wednesday that the company will return at least 60% of ordinary net income to shareholders via dividends, so there's upside to that payout.

Dupont Fabros Technology (DFT): Data center REITs are such a good idea and DFT's three biggest tenants --Facebook (FB), Microsoft (MSFT) and Yahoo! (YHOO) -- are unlikely to go out of business. Yield: 5.57%.

Goodrich Petroleum (GDP): Oil prices will recover. GDP has options to increase liquidity, including sale of its Eagle Ford assets and potential joint venture in its core Tuscaloosa Marine Shale play.

Magnum Hunter Resources (MHR): I would say ditto to GDP, but contrary to the market's perception, MHR doesn't drill for much oil; production is more than 90% natural gas, on which I'm bullish. Impending sale of 45% stake in Eureka Hunter pipeline will address liquidity concerns with finality.

MannKind (MNKD): MNKD's Afrezza inhalable insulin delivery system is truly a game-changer in the diabetes treatment space. But Afrezza seemed to hit the market with a thud after its launch in February, and the stock crashed down to $3.46 after initial sales results disappointed. It was a case of "too soon" as this was always going to be a gradual, methodical rollout, and there is just no way marketing partner Sanofi (SNY) is going to let Afrezza die on the vine.

Newtek Business Services (NEWT): Newtek recently underwent the transition to a business development company and still needs to distribute excess retained income. I expect an announcement on special dividend timing/size in the very near future. In the meantime, the regular dividend yield of 9.97% is tasty.

Second Sight Medical Products (EYES): Huge news Wednesday as Argus II was implanted in a patient with age-related macular degeneration for the first time. I defy you to watch this video and not buy the stock.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins was long all stocks mentioned above except AAPL, although positions may change at any time.

TAGS: Investing | U.S. Equity | Technology

More from Technology

SoFi Technologies Is Primed for a Rebound

Bruce Kamich
May 16, 2022 8:50 AM EDT

Here's where the shares may be headed next.

A 'Mag'nificent Way to Play an AdTech Rebound

Bret Jensen
May 15, 2022 9:15 PM EDT

Similar to biotech, the small adtech space has been hammered in recent quarters and has likely hit oversold territory.

SOS! General Apple, General Microsoft Are Under Fire!

Ed Ponsi
May 13, 2022 10:30 AM EDT

In a blow to the bulls, AAPL and MSFT surrender to the inevitable, as Chief Powell aims a bazooka at inflation.

Micron Technology Could Sink Even Further in the Weeks Ahead

Bruce Kamich
May 13, 2022 10:00 AM EDT

Here's what has us worried -- and how low the stock could go.

It's OK to Track ARKK for Bottom Clues, but Don't Go Down With the Ship

Bob Byrne
May 13, 2022 8:30 AM EDT

Cathie Wood's ARK Innovation ETF and its constituent stocks bounced on Thursday, though they collectively remain deep in bear market territory.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:14 PM EDT PAUL PRICE

    A New, Very Scary Movie

  • 08:51 AM EDT PAUL PRICE

    Advice From the Future...

  • 12:20 PM EDT PAUL PRICE

    A Blast From the Past Regarding Bitcoin

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login